BN/SB/08A/B

## IAP20 REC'OF CTIPTO 13 JAN 2006

Substitute for form 1449A/PTO				Complete if Known		
•				Application Number	Noty this prod 64620	
INFORMATION DISCLOSURE			CLOSURE	Filing Date	Evaluate herewith	
STAT	STATEMENT BY APPLICANT			First Named Inventor	Pnina FISHMAN	
• • • • • • • • • • • • • • • • • • • •		• • • • • • • • • • • • • • • • • • • •	. 2.07	Group Art Unit		
(use as many sheets as necessary)			ecessary)	Examiner Name		
Sheet	1	of	1	Attorney Docket Number	FISHMAN18A	

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	Cite No.	Document Number Number-Kind Code <sup>x (tr</sup> known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US- 5,773,423 A	06-30-1998	Jacobson et al.	
		US-			

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Number	Dublication Date	Name of Patentee or Applicant	Pages, Columns, Lines,	
Examiner Initials*	Cite No.1	Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY		Where Relevant Passages or Relevant Figures Appear	T°

		NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION					
Examiner Cite Initials* No.							
M·C+		Bonvini, P. et al., "Nuclear β-catenin displays GSK-3β- and APC-independent proteasome sensitivity in melanoma cells", Biochim. BioBiophys. Acta., (2000), Vol. 1495, pp. 308-318.					
	AC	Fang, X. et al., "Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A", Proc. Natl. Acad. Sci. (2000), Vol. 97, pp. 11960-11965.					
	AD	Ferkey, D. M., et al., :GSK-3: New Thoughts on an Old Enzyrne*, Dev. Biol. (2000), Vol. 225, pp. 471-479.					
	AE	Fishman, P. et al., "Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells" Oncogene, (2002), Vol. 21, pp. 4060-4064.					
	AF	Lee, Z. H., et al., "Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts", Biochemical and Biophysical Research Comm. (2003), Vol. 305, pp. 211-214.					
	AG	Olah, M. E., et al., "The role of receptor structure in determining adenosine receptor activity", Pharmacol. Ther. (2000), Vol. 85, pp. 55-75.					
		Poulsen, S. et al., "Adenosine Receptors: New Opportunities for Future Drugs", Biorganic & Med. Chem, (1998), Vol. 6, pp. 619-641.					
	AI	Szabo, C. et al., "Suppression of macrophage inflammatory protein (MIP)-1a production and collagen-induced arthritis by adenosine receptor agonists", British Journal of Pharmacology, (1998), Vol. 125, pp. 379-387.					
—!- M:c:H	AJ	Walsh, N. C., et al., "Bone loss in inflammatory arthritis: mechanisms and treatment strategies", Current Opinion in Rheumatology, (2004), Vol. 16, pp. 419-427.					

Examiner Signature	AP-7	Date Considered	1/2/08

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Potent Documents at <a href="https://www.uspio.gov">www.uspio.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For applicant documents, the indication of the year of the reign of the Emperor unsty precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

î

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known					
Application Number	10/564,620				
Filing Date	January 13, 2006				
First Named Inventor	Pnina FISHMAN				
Group Art Unit	1614	<del></del>			
Examiner Name	Not Yet Known				
Attorney Docket Number	FISHMAN=18A				

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code <sup>2 (II</sup> Number-Kind Code <sup>2 (II</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
1		US-				
i		US-				
		US-				
		US-				
		US-				
•						

		FORE	IGN PATENT DO	OCUMENTS		
Examiner Initials*		Foreign Patent Number Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁰
MOH	AK	WO 2005/084653 A2	09-15-2005	CAMBRIDGE BIOTECHNOLOGY LIMITED		
	AL	WO 2004/045627 A1	06-03-2004	CAN-FITE BIOPHARMA LTD.		
	АМ	WO 2004/078184 A1	09-16-2004	CAMBRIDGE BIOTECHNOLOGY LIMITED		
	AN	WO 01/19360 A2	03-22-2001	CAN-FITE TECHNOLOGIES LTD.		
	AO	WO 00/72799 A2	12-07-2000	THE UNIVERSITY OF VIRGINIA PATENT FOUNDATION		
MCH	AP	WO 01/019380 A3	03-22-2001	CAN-FITE BIOPHARMA LTD.		
					1	<u> </u>

Examiner Signature	Date Considered	1/21/08	
-----------------------	--------------------	---------	--

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.